Natixis Advisors L.P. Boosts Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Natixis Advisors L.P. boosted its stake in shares of Natera, Inc. (NASDAQ:NTRAFree Report) by 29.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,553 shares of the medical research company’s stock after acquiring an additional 4,497 shares during the period. Natixis Advisors L.P.’s holdings in Natera were worth $1,224,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of NTRA. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Natera by 19.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,616 shares of the medical research company’s stock worth $912,000 after buying an additional 3,384 shares in the last quarter. Assetmark Inc. grew its stake in shares of Natera by 16.5% in the 3rd quarter. Assetmark Inc. now owns 3,899 shares of the medical research company’s stock worth $173,000 after buying an additional 552 shares in the last quarter. Zevenbergen Capital Investments LLC grew its stake in shares of Natera by 6.2% in the 3rd quarter. Zevenbergen Capital Investments LLC now owns 432,892 shares of the medical research company’s stock worth $19,155,000 after buying an additional 25,285 shares in the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of Natera in the 3rd quarter worth $358,000. Finally, Banque Pictet & Cie SA grew its stake in shares of Natera by 7.3% in the 3rd quarter. Banque Pictet & Cie SA now owns 142,850 shares of the medical research company’s stock worth $6,321,000 after buying an additional 9,755 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Trading Up 1.7 %

Shares of NTRA opened at $107.31 on Thursday. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $108.32. The company has a 50-day moving average of $93.28 and a 200 day moving average of $72.87. The firm has a market capitalization of $13.18 billion, a price-to-earnings ratio of -34.39 and a beta of 1.38. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.12 and a quick ratio of 3.96.

Natera (NASDAQ:NTRAGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business had revenue of $367.70 million during the quarter, compared to analyst estimates of $316.31 million. During the same quarter in the previous year, the business posted ($1.23) EPS. The company’s quarterly revenue was up 52.1% compared to the same quarter last year. On average, research analysts expect that Natera, Inc. will post -2.35 EPS for the current year.

Insider Activity

In other news, CEO Steven Leonard Chapman sold 9,326 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $88.36, for a total value of $824,045.36. Following the completion of the sale, the chief executive officer now owns 246,957 shares in the company, valued at approximately $21,821,120.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Steven Leonard Chapman sold 9,326 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $88.36, for a total value of $824,045.36. Following the completion of the sale, the chief executive officer now owns 246,957 shares in the company, valued at approximately $21,821,120.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Herm Rosenman sold 93,901 shares of Natera stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $69.37, for a total transaction of $6,513,912.37. Following the completion of the transaction, the director now directly owns 61,685 shares in the company, valued at approximately $4,279,088.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 410,750 shares of company stock worth $35,002,520. 7.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have commented on NTRA shares. Stephens reissued an “overweight” rating and issued a $78.00 price objective on shares of Natera in a research note on Tuesday, January 30th. Piper Sandler raised their target price on shares of Natera from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Tuesday. The Goldman Sachs Group raised their target price on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, April 15th. Raymond James lowered shares of Natera from a “strong-buy” rating to an “outperform” rating and raised their target price for the stock from $68.00 to $85.00 in a report on Tuesday, February 20th. Finally, Craig Hallum initiated coverage on shares of Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 target price for the company. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $98.47.

View Our Latest Report on Natera

Natera Company Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Articles

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRAFree Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.